ABP-745 Phase II Trial Enrollment: Atom Therapeutics has enrolled the first patient in a global Phase II study of ABP-745, a ...

Gout, a painful arthritis caused by uric acid buildup, triggers flare-ups worsened by genetics, diet, alcohol, or medication.

Atom has enrolled the first patient in a multi-country Phase 2 trial of ABP-745 for treatment of painful acute gout flares.

Patients who use NSAIDs for paradoxical gout flare prevention when starting allopurinol demonstrate greater risk for adverse cardiovascular outcomes vs. those who use colchicine, according to data ...

"Acute Gout Flare Market 2034 by DelveInsight"The report analyzes the existing treatment practices and unmet medical requirements in Acute Gout Flare. It evaluates ...

The FDA has accepted for review the BLA for nanoencapsulated sirolimus plus pegadricase in the treatment of uncontrolled gout.

The gout market is poised for steady growth, driven by the rising prevalence of the disease, increasing awareness, and the launch of novel therapies such as AR-882, Epaminurad, XNW3009, XRx-026, ...

Many mistake gout for arthritis, delaying proper treatment and worsening the condition. Gout, caused by uric acid crystal ...

One day you wake up feeling fine, and the next day you suddenly can't even walk. For most people, the pain is unbearable and ...

Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition. | Atom Therapeutics is touting data from ...

Gout is a painful form of arthritis caused by high uric acid levels that form sharp crystals in the joints, leading to swelling, stiffness, and intense discomfort. While genetics and medical ...

Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, ...